(Q37887170)

24 August 2017

1 reference

title

Antibiotic treatment of CF lung disease: from bench to bedside (English)

1 reference

24 August 2017

1 reference

Robert Bals

1

1 reference

24 August 2017

Dominique Hubert

series ordinal

2

1 reference

24 August 2017

Burkhard Tümmler

series ordinal

3

1 reference

24 August 2017

publication date

1 June 2011

1 reference

Journal of Cystic Fibrosis

24 August 2017

published in

1 reference

24 August 2017

volume

10 Suppl 2

1 reference

24 August 2017

page(s)

S146-51

1 reference

Cystic fibrosis mortality and survival in the UK: 1947-2003

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

1 reference

7 January 2021

Microbiology of airway disease in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

The changing microbial epidemiology in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Detection of Anaerobic Bacteria in High Numbers in Sputum from Patients with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

A 96-well-plate-based optical method for the quantitative and qualitative evaluation of Pseudomonas aeruginosa biofilm formation and its application to susceptibility testing

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Aerosol antibiotics in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Has nature already identified all useful antibacterial targets?

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Robust Salmonella metabolism limits possibilities for new antimicrobials.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Role of LecA and LecB lectins in Pseudomonas aeruginosa-induced lung injury and effect of carbohydrate ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Multiple activities of c-di-GMP in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Quorum-sensing blockade as a strategy for enhancing host defences against bacterial pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Computer-aided identification of recognized drugs as Pseudomonas aeruginosa quorum-sensing inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: a promising strategy or an oriental mystery?

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

The clinical use of colistin in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Temocillin in cystic fibrosis: a retrospective pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Old dogma, new tricks--21st Century phage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

1 reference

7 January 2021

Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3).

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

Where have all the antibiotic patents gone?

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2811%2960019-2

7 January 2021

10.1016/S1569-1993(11)60019-2

Identifiers

DOI

1 reference

24 August 2017

1 reference